- Home
- DXR vs RPID Comparison
DXR vs RPID Comparison
Compare DXR & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- RPID
- Stock Information
- Founded
- DXR 1970
- RPID 2006
- Country
- DXR United States
- RPID United States
- Employees
- DXR N/A
- RPID N/A
- Industry
- DXR Medical/Dental Instruments
- RPID Medical Specialities
- Sector
- DXR Health Care
- RPID Health Care
- Exchange
- DXR Nasdaq
- RPID Nasdaq
- Market Cap
- DXR 37.6M
- RPID 43.5M
- IPO Year
- DXR N/A
- RPID 2021
- Fundamental
- Price
- DXR $8.22
- RPID $1.36
- Analyst Decision
- DXR Strong Buy
- RPID
- Analyst Count
- DXR 1
- RPID 0
- Target Price
- DXR $24.75
- RPID N/A
- AVG Volume (30 Days)
- DXR 6.8K
- RPID 146.3K
- Earning Date
- DXR 01-01-0001
- RPID 02-28-2025
- Dividend Yield
- DXR N/A
- RPID N/A
- EPS Growth
- DXR N/A
- RPID N/A
- EPS
- DXR 0.35
- RPID N/A
- Revenue
- DXR $154,205.00
- RPID $26,170,000.00
- Revenue This Year
- DXR N/A
- RPID $24.34
- Revenue Next Year
- DXR N/A
- RPID $19.49
- P/E Ratio
- DXR $24.39
- RPID N/A
- Revenue Growth
- DXR N/A
- RPID 27.31
- 52 Week Low
- DXR $7.19
- RPID $0.58
- 52 Week High
- DXR $10.00
- RPID $1.45
- Technical
- Relative Strength Index (RSI)
- DXR 49.04
- RPID 66.73
- Support Level
- DXR $8.01
- RPID $1.17
- Resistance Level
- DXR $8.50
- RPID $1.43
- Average True Range (ATR)
- DXR 0.28
- RPID 0.13
- MACD
- DXR 0.09
- RPID 0.04
- Stochastic Oscillator
- DXR 72.98
- RPID 79.33
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.